This multibagger AI stock has received a "Buy" rating and price upgrade from a Citi analyst with strong support on Wall Street.
Even after a steep pullback, DocuSign could surge over 170% if it hits the $124 Street-high target set by Citizens, indicating a bold turnaround call.
Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.
Summary The Travelers Companies (TRV) demonstrates strong technical momentum, with a Trend Seeker 'Buy' signal and 9.54% gain over the past month. TRV trades at an 11.01x trailing P/E, notably below the...
Two beverage giants battle over dividends, cash flow, and growth. Which income stock comes out on top for investors?
Despite falling mortgage rates and low inventory, homebuilding hasn't taken off like you might expect. Here's what's keeping ITB down right now.
The nation's biggest energy provider has reversed plans to retire two major coal plants. The decision has serious implications for energy markets moving forward, and investors need to react accordingly....
Although General Dynamics has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.
Of the top 100 Vol/OI ratios in Thursday’s trading, 52 unusually active options expire on March 20. Nineteen of the stocks had Vol/OI ratios higher than 23.69. Three will make you money with these options...
Uber just launched its air taxi service, and the company's autonomous vehicle push is accelerating. Here's what investors need to know.
